



Vertex Pharmaceuticals (Europe) Ltd
Level 9, Paddington Central
2 Kingdom Street
London
W2 68D

04 July 2017

Professor Nataliya Kashirskaya
Department of genetic epidemiology (Cystic Fibrosis Group)
Research Care for Medical Genetics,
Ul. Moskvorechie, 1,
Moscow, Russia 115478

Dear Nataliya and Elena,

I know that the Russian CF community is keenly awaiting news on access to Kalydeco and Orkambi, so I wanted to take the opportunity to update you on Vertex's ongoing efforts to get our medicines to people with CF in Russia. I understand the community's concerns and share your sense of urgency in finding a solution.

As I understand you discussed during your meeting with the Vertex team at the recent European Cystic Fibrosis Society (ECFS) Conference in Seville, we have been working tirelessly for more than one and a half years to find a way to get our medicines into Russia. Unfortunately, despite these efforts, we have, so far, been unable to find a partner that meets the standards required by U.S. foreign practices laws. I appreciate the ideas you proposed; we have already started investigating these different potential pathways and will keep you updated as we have information to share.

Please know that as a company and individuals we remain committed to progressing in our fight against CF and giving it our all everyday. I realise that I don't have all the answers you're looking for at this stage, but I hope I've been able to provide some context on where things stand. I can assure you that Vertex remains committed to finding a compliant solution for delivering our medicines to the CF community in Russia. Thank you for the constructive meeting at ECFS and the clear next steps agreed. We look forward to continuing our collaboration in the future.

Kind Regards,

A handwritten signature in black ink, appearing to read "Simon Bedson".

Simon Bedson
Senior Vice President, International General Manager
Vertex